_id
691853fa3c536f8df2317880
Ticker
0A3M.LSE
Name
BioNTech SE
Exchange
LSE
Address
An der Goldgrube 12, Mainz, Germany, 55131
Country
UK
Sector
Industry
Currency
USD
Website
https://www.biontech.de
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Last Close
97.75
Volume
1741
Current Price
99.48
Change
1.6574
Last Updated
2026-01-08T13:27:59.876Z
Image
https://logo.clearbit.com/www.biontech.de
Ipo Date
-
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2023-09-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
-
Operating Income
-
Interest Expense
-
Pretax Income
-
Net Income
-
Eps
-
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
66800000
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
-
Short Term Investments
-
Receivables
2298100000
Inventories
415700000
Total Current Assets
18749100000
Property Plant Equipment
925900000
Total Assets
-
Payables
222700000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
1807200000
Equity
-
Bs_currency_symbol
USD
Depreciation
41300000
Change In Working Capital
-
Cash From Operations
811200000
Capital Expenditures
54000000
Cash From Investing
-1232200000
Cash From Financing
-311000000
Net Change In Cash
-670800000
Cf_currency_symbol
USD
PE
0.032
PB
-
ROE
-
ROA
-
FCF
757200000
Fcf Percent
-
Piotroski FScore
1
Health Score
46
Deep Value Investing Score
3
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
1.5
Garp Investing Score
0
Growth Investing Score
0
Momentum Investing Score
2.5
Net Net Investing Score
0
Quality Investing Score
0.5
Value Investing Score
4.5
Quarters > 0 > quarter
2023-09-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
-
Quarters > 0 > income Statement > operating Income
-
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-
Quarters > 0 > income Statement > net Income
-
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
66800000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
2298100000
Quarters > 0 > balance Sheet > inventories
415700000
Quarters > 0 > balance Sheet > total Current Assets
18749100000
Quarters > 0 > balance Sheet > property Plant Equipment
925900000
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
222700000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1807200000
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
160600000
Quarters > 0 > cash Flow > depreciation
41300000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
811200000
Quarters > 0 > cash Flow > capital Expenditures
54000000
Quarters > 0 > cash Flow > cash From Investing
-1232200000
Quarters > 0 > cash Flow > cash From Financing
-311000000
Quarters > 0 > cash Flow > net Change In Cash
-670800000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
757200000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
46
Quarters > 1 > quarter
2023-06-30
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
-
Quarters > 1 > income Statement > operating Income
-
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-
Quarters > 1 > income Statement > net Income
-
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
-
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
-
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
-
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
-
Quarters > 1 > balance Sheet > equity
-
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-190400000
Quarters > 1 > cash Flow > depreciation
41300000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
811200000
Quarters > 1 > cash Flow > capital Expenditures
54000000
Quarters > 1 > cash Flow > cash From Investing
-1232200000
Quarters > 1 > cash Flow > cash From Financing
-311000000
Quarters > 1 > cash Flow > net Change In Cash
-670800000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-
Quarters > 1 > ratios > ROA
-
Quarters > 1 > ratios > FCF
757200000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
46
Quarters > 2 > quarter
2023-03-31
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
-
Quarters > 2 > income Statement > operating Income
-
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-
Quarters > 2 > income Statement > net Income
-
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
-
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
-
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
-
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
-
Quarters > 2 > balance Sheet > equity
-
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
502200000
Quarters > 2 > cash Flow > depreciation
41300000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
811200000
Quarters > 2 > cash Flow > capital Expenditures
54000000
Quarters > 2 > cash Flow > cash From Investing
-1232200000
Quarters > 2 > cash Flow > cash From Financing
-311000000
Quarters > 2 > cash Flow > net Change In Cash
-670800000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
-
Quarters > 2 > ratios > ROA
-
Quarters > 2 > ratios > FCF
757200000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2022-12-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
-
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
-
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
2278700000
Quarters > 3 > cash Flow > depreciation
41300000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
811200000
Quarters > 3 > cash Flow > capital Expenditures
54000000
Quarters > 3 > cash Flow > cash From Investing
-1232200000
Quarters > 3 > cash Flow > cash From Financing
-311000000
Quarters > 3 > cash Flow > net Change In Cash
-670800000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
757200000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
46
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
-
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
-
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
9434400000
Annuals > 0 > cash Flow > depreciation
-
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
-
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
-
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
4753900000
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
12382100000
Annuals > 1 > balance Sheet > inventories
502500000
Annuals > 1 > balance Sheet > total Current Assets
15072300000
Annuals > 1 > balance Sheet > property Plant Equipment
520400000
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
160000000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
3481600000
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
10292500000
Annuals > 1 > cash Flow > depreciation
75200000
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
889700000
Annuals > 1 > cash Flow > capital Expenditures
127500000
Annuals > 1 > cash Flow > cash From Investing
-566100000
Annuals > 1 > cash Flow > cash From Financing
94200000
Annuals > 1 > cash Flow > net Change In Cash
482500000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
762200000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
46
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
482325000
Annuals > 2 > income Statement > cost Of Revenue
59333000
Annuals > 2 > income Statement > gross Profit
422992000
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
-82417000
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-145802000
Annuals > 2 > income Statement > net Income
15198000
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
-161000000
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-17.087441040791997
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
1210209000
Annuals > 2 > balance Sheet > short Term Investments
137234000
Annuals > 2 > balance Sheet > receivables
166400000
Annuals > 2 > balance Sheet > inventories
64100000
Annuals > 2 > balance Sheet > total Current Assets
1666900000
Annuals > 2 > balance Sheet > property Plant Equipment
326000000
Annuals > 2 > balance Sheet > total Assets
2318620000
Annuals > 2 > balance Sheet > payables
102300000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
153016000
Annuals > 2 > balance Sheet > total Liabilities
946774000
Annuals > 2 > balance Sheet > equity
1371846000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
15198000
Annuals > 2 > cash Flow > depreciation
38700000
Annuals > 2 > cash Flow > change In Working Capital
-94903000
Annuals > 2 > cash Flow > cash From Operations
-13500000
Annuals > 2 > cash Flow > capital Expenditures
66000000
Annuals > 2 > cash Flow > cash From Investing
-144800000
Annuals > 2 > cash Flow > cash From Financing
894700000
Annuals > 2 > cash Flow > net Change In Cash
691100000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
1.1078502980655263
Annuals > 2 > ratios > ROA
0.6554761021642184
Annuals > 2 > ratios > FCF
-79500000
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
-0.16482662105426837
Annuals > 2 > health Score
34
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
108589000
Annuals > 3 > income Statement > cost Of Revenue
17361000
Annuals > 3 > income Statement > gross Profit
91228000
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
-181518000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-179440000
Annuals > 3 > income Statement > net Income
-179056000
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
-200000
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-167.16057795909347
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
519149000
Annuals > 3 > balance Sheet > short Term Investments
1680000
Annuals > 3 > balance Sheet > receivables
20205000
Annuals > 3 > balance Sheet > inventories
12073000
Annuals > 3 > balance Sheet > total Current Assets
560151000
Annuals > 3 > balance Sheet > property Plant Equipment
148062000
Annuals > 3 > balance Sheet > total Assets
797647000
Annuals > 3 > balance Sheet > payables
20498000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
14777000
Annuals > 3 > balance Sheet > total Liabilities
304155000
Annuals > 3 > balance Sheet > equity
493492000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-179056000
Annuals > 3 > cash Flow > depreciation
33900000
Annuals > 3 > cash Flow > change In Working Capital
-84102000
Annuals > 3 > cash Flow > cash From Operations
-198500000
Annuals > 3 > cash Flow > capital Expenditures
38600000
Annuals > 3 > cash Flow > cash From Investing
-77200000
Annuals > 3 > cash Flow > cash From Financing
383300000
Annuals > 3 > cash Flow > net Change In Cash
107600000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-36.283465588094636
Annuals > 3 > ratios > ROA
-22.44802525427915
Annuals > 3 > ratios > FCF
-237100000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-2.1834624133199494
Annuals > 3 > health Score
32
Valuation > metrics > PE
0.032
Valuation > final Score
70
Valuation > verdict
99.7% Undervalued
Profitability > final Score
50
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
84.18994162550517
Liquidity > metrics > Quick Ratio
82.32330489447688
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
50
Prev Profitabilities > 1
50
Prev Profitabilities > 2
50
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2026-01-20T22:52:10.656Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-10
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.06
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-03
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.1395
Earnings History > 1 > eps Estimate
0.1
Earnings History > 1 > eps Difference
-0.2395
Earnings History > 1 > surprise Percent
-239.5
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-04
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.8242
Earnings History > 2 > eps Estimate
-1.41
Earnings History > 2 > eps Difference
-0.4142
Earnings History > 2 > surprise Percent
-29.3759
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-16
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-1.8208
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2024-12-31
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
1.1535
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-04
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
0.8898
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-05
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-3.6581
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-06
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-1.4218
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-20
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
2.0359
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-12-18
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
0.7289
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-07
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.8642
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-08
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
2.1995
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-27
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
9.4457
Earnings History > 12 > eps Estimate
-
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-07
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
7.0269
Earnings History > 13 > eps Estimate
-
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-08
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
6.8645
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-09
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
15.9749
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-30
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
14.9225
Earnings History > 16 > eps Estimate
-
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-09
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
14.5572
Earnings History > 17 > eps Estimate
-
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-09
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
12.9846
Earnings History > 18 > eps Estimate
-
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-10
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
5.2877
Earnings History > 19 > eps Estimate
-
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2020-12-31
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
1.8111
Earnings History > 20 > eps Estimate
-
Earnings History > 20 > eps Difference
0
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-09-30
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-1.0285
Earnings History > 21 > eps Estimate
-
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
-
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2023-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
* Institutions hold a combined 0.00% of the total shares of BioNTech SE
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.06
Date
2025-09-30
EPS Actual
-0.1395
EPS Estimate
0.1
EPS Difference
-0.2395
Surprise Percent
-239.5%
(Last Updated 2023-09-30)
(Last Updated 2023-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2023-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2023-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.